Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Verastem Inc (VSTM) Common Stock USD 0.0001

Sell:$2.63 Buy:$2.70 Change: $0.01 (0.37%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Change: $0.01 (0.37%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Change: $0.01 (0.37%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.

Contact details

117 Kendrick St Ste 500
United States
+1 (781) 2924200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$460.06 million
Shares in issue:
171.67 million
United States
US dollar

Key personnel

  • Daniel Paterson
    President, Chief Operating Officer
  • Brian Stuglik
    Chief Executive Officer, Director
  • Robert Gagnon
    Chief Financial Officer, Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.